Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
AI, Machine Learning & Computational Drug Design | Q&As & Interviews

Interview with Sridevi Nagarajan, Head Digital Regulatory Strategy at AstraZeneca

Edited by Tia Byer | 01 November 2023
AstraZeneca’s Sridevi Nagarajan discusses the importance of artificial intelligence, strategic collaboration, and the role of the metaverse in unlocking the future of digital regulatory.
https://youtu.be/dy2-Mg884CY

Disclaimer: The information & experiences conveyed in this interview belong to Sridevi Nagarajan and not AstraZeneca as an organization.

Get your weekly dose of industry news and announcements here, and keep up to date with the latest ‘Industry Spotlight’ posts. For other PharmaTec content, please visit the PharmaTec Content Portal.

Want to find out more about the innovations happening in pharma data? Join Oxford Global’s annual Pharma Data & Digital Medicine event today. This 2-day conference brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and exciting industry outlooks.

Speaker Biographies

Sridevi Nagarajan is a senior strategic data-driven portfolio management professional with 20 years’ experience of leading and delivering successful digital transformation outcomes across Pharmaceutical and Public Health sectors. A collaborative innovator who enjoys building relationships and utilising data to navigate corporations through periods of business transformations. Motivated and influential leader with high level analytical skills and expertise in drug development, clinical, regulatory, digital, Information management and governance. Track record of surpassing goals in business benefit realizations through Simplification and Tech Transformation programs. Influencer and Change Leader working with multiple stakeholders including government, academic and industry partners to achieve Organizational Growth.

Related Resources

Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre

Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.
Read More

AI-driven High Throughput Screening for Targeted Drug Discovery

Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
20/03/24
The Design of Novel Drugs with Generative AI
28/03/24
Generative AI and Large Language Models for Quantitative and Systems Pharmacology